Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
Biogen, Eisai’s Leqembi Suffers Overseas Setbacks as UK Denies Coverage, Australia Denies Approval
Days after suffering a rejection in Australia, the Alzheimer’s drug hit another roadblock in the U.K., which found the drug ...
TOKYO -- Japanese drugmaker Eisai's share price is hovering around a 10-year low of 4,300 yen, weighed down by poor U.S.
The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's ...
Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...
England’s National Institute for Health and Care Excellence (NICE) has given a second thumbs down to a pair of Alzheimer’s ...
An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...
Japanese drugmaker Eisai Inc. will lay off 57 employees in Nutley between the end of March and May, public records show, as the pharmaceutical company shaves off 7% of its U.S. workforce. The New ...
Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.
Eisai Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer's Disease in Australia TOKY ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback